
Quebec drug maker recalls pain medicine amid potentially fatal health risks
Global News
Health Canada said the mix-up could cause patients to get a larger dose of painkiller than prescribed, possibly resulting in an overdose with 'potentially fatal health risks.'
JAMP Pharma Corp., a Quebec pharmaceutical maker, is recalling one lot of JAMP-Pregabalin pain medicine because bottles labelled to contain 50-milligram capsules may contain 150-milligram capsules instead.
Health Canada announced the recall in an unusual Saturday evening statement.
The announcement said the company’s mix-up could lead to patients taking a much larger dose of the painkiller than prescribed, possibly resulting in an overdose that could “pose serious, potentially fatal health risks.”
JAMP-Pregabalin is an adult prescription drug. It is used to treat pain caused by nerve damage due to diabetes, shingles or spinal cord injury. It is also used to treat pain associated with fibromyalgia, Health Canada said.
The recall affects one lot of the 50-mg capsules bearing lot number 2305012747, which carries a 2026-08 expiry date, Health Canada said.
Health Canada stressed that taking too much pregabalin or suddenly increasing the dose could potentially lead to patients overdosing, which can be life-threatening.
The government urged both ordinary patients and health professionals, such as pharmacists, to check the contents of their JAMP-Pregabalin 50-mg bottles and see if they contain 150-mg capsules.
The agency warned that symptoms of pregabalin overdose may include sudden mood changes, sleepiness, confusion, depression, agitation, restlessness and seizures. It urged anyone taking the medication experiencing such symptoms to seek immediate medical attention.













